The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 10, 2024

Filed:

Jun. 16, 2021
Applicant:

Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);

Inventors:

Susannah Brydges, Putnam Valley, NY (US);

Yajun Tang, White Plains, NY (US);

Yang Liu, Valhalla, NY (US);

Jingtai Cao, White Plains, NY (US);

Carmelo Romano, Tarrytown, NY (US);

Assignee:

Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12N 5/00 (2006.01); A01K 67/0276 (2024.01); A01K 67/0278 (2024.01); C07K 14/47 (2006.01); C12N 15/85 (2006.01); G01N 33/50 (2006.01); G01N 33/68 (2006.01);
U.S. Cl.
CPC ...
A01K 67/0278 (2013.01); A01K 67/0276 (2013.01); C07K 14/47 (2013.01); C12N 15/8509 (2013.01); G01N 33/5088 (2013.01); G01N 33/6893 (2013.01); A01K 2217/054 (2013.01); A01K 2217/072 (2013.01); A01K 2217/075 (2013.01); A01K 2217/15 (2013.01); A01K 2217/206 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0306 (2013.01); A01K 2267/0393 (2013.01); C12N 2015/8527 (2013.01); C12N 2015/8536 (2013.01); C12N 2510/00 (2013.01); C12N 2800/30 (2013.01); C12N 2830/008 (2013.01);
Abstract

Non-human animals suitable for use as animal models for Retinoschisis are provided. In some embodiments, provided non-human animals are characterized by a disruption in a Retinoschisin-1 locus. In some embodiments, provided non-human animals are characterized by a mutant Retinoschisin-1 gene. The non-human animals may be described, in some embodiments, as having a phenotype that includes the development of one or more symptoms or phenotypes associated with Retinoschisis. Methods of identifying therapeutic candidates that may be used to prevent, delay or treat Retinoschisis or eye-related diseases, disorders or conditions are also provided.


Find Patent Forward Citations

Loading…